Welcome to our dedicated page for Intuitive Surgical SEC filings (Ticker: ISRG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Intuitive Surgical filings document operating results, governance matters, capital structure, and material events for a Nasdaq-listed medical technology company focused on robotic-assisted surgery. Its Form 8-K reports furnish quarterly and preliminary financial results, procedure information, and exhibits tied to da Vinci and Ion business performance.
Regulatory filings also cover shareholder voting matters, proxy governance, executive compensation, director elections, and officer-role changes. Other material-event disclosures record completed corporate actions, including the acquisition of da Vinci and Ion distribution operations in Europe, alongside formal disclosures about common stock and financial reporting matters.
Intuitive Surgical senior executive Iman Jeddi filed an initial statement of ownership, detailing equity awards and indirect common stock holdings. As of January 29, 2026, a trust associated with Jeddi held 26,649 shares of Intuitive Surgical common stock. Jeddi also directly holds several non-qualified stock options and stock units. These include options to buy 5,625, 3,760, 5,028, 3,760 and 5,028 shares of common stock at exercise prices ranging from $76.9989 to $304.67 per share, with expirations between August 2026 and August 2030. The filing further lists performance stock units of 2,702 and 5,585 shares for which performance criteria have been achieved, vesting in 2027 and 2026, and multiple restricted stock unit grants totaling several thousand shares that vest over a four-year schedule.
Intuitive Surgical executive Patricia L. Wadors, SVP and Chief Human Resources Officer, filed an initial ownership report showing she directly holds two blocks of restricted stock units (RSUs) in Intuitive Surgical common stock. One award covers 6,419 RSUs that vest 25% each year on October 10 starting in 2024, and another covers 1,831 RSUs that vest 25% each year on February 26 starting in 2025. Each RSU converts into one share of common stock when it vests, conditioned on her continued service with the company.
Intuitive Surgical provides robotic-assisted systems, instruments, services, and digital tools that support minimally invasive care, led by its da Vinci surgical platforms and Ion lung biopsy system. The company focuses on improving patient outcomes, care-team experience, access to care, and total cost per treatment episode.
Its ecosystem includes stapling and energy instruments, training pathways, simulation (SimNow), analytics (Custom Hospital Analytics, My Intuitive), and comprehensive field service. For the year ended December 31, 2025, domestic revenue represented 68% of total revenue, with 32% generated outside the U.S. The company highlights extensive business, regulatory, and technology risks, including intense competition, global macroeconomic pressures, supply chain dependence, evolving data and AI regulations, and complex FDA and international compliance obligations.
Intuitive Surgical director Keith R. Leonard reported a change in his holdings of Intuitive Surgical, Inc. common stock. On 01/29/2026, 369 shares of common stock were transferred at a price of $0.0 per share, coded as transaction type "J" for “other.”
The footnote explains this was a transfer of shares pursuant to a divorce decree, indicating a personal, court-directed reallocation rather than an open‑market trade. After this transaction, Leonard beneficially owns 370 shares of Intuitive Surgical common stock in direct form.
Intuitive Surgical executive Mark Brosius reported new performance-based equity awards. On January 28, 2026, he was credited with 2,702 performance stock units tied to a grant dated February 26, 2024 and 5,585 performance stock units tied to a grant dated February 28, 2023.
The company’s compensation committee determined the performance criteria for both awards had been achieved. The 2024-related units are scheduled to vest on February 26, 2027, and the 2023-related units on February 28, 2026, in each case requiring Brosius to remain in continuous service until those vesting dates.
Intuitive Surgical executive Gary Loeb reported performance-based equity awards. On January 28, 2026, he acquired 2,543 performance stock units tied to a February 26, 2024 grant and 2,098 performance stock units tied to a February 28, 2023 grant, each at a stated price of 0.0 per unit.
The company’s compensation committee determined that required performance goals were achieved. The 2023-related units are scheduled to vest on February 28, 2026, and the 2024-related units on February 26, 2027, in each case contingent on Loeb’s continued service with Intuitive Surgical.
Intuitive Surgical’s Chief Executive Officer and director David J. Rosa reported grants of performance stock units that have now been earned based on previously set goals. On January 28, 2026, he acquired 6,360 PSUs from a February 26, 2024 grant, 9,575 PSUs from a February 28, 2023 grant, and 6,034 PSUs from a June 12, 2023 grant.
The compensation committee confirmed that the performance criteria for each grant were achieved. These PSUs convert into common stock if Rosa remains in continuous service through the vesting dates: February 26, 2027 for the 2024 grant and February 28, 2026 for the 2023 and June 2023 grants.
Intuitive Surgical EVP & Chief Medical Officer Myriam Curet reported option and stock transactions plus performance stock units. On January 29, 2026, she exercised 126 non-qualified stock options at $208.9 per share and sold 126 common shares at $520.02 per share under a Rule 10b5-1 trading plan that expires July 29, 2026.
Following these trades, she reported no directly held common stock and 353 common shares held indirectly through a trust. Separately, on January 28, 2026, 5,585 performance stock units granted on February 28, 2023 were reported after the company confirmed performance goals were achieved; these PSUs are scheduled to vest on February 28, 2026, subject to continued service.
Intuitive Surgical director Gary S. Guthart reported new performance-based equity awards. On January 28, 2026, he acquired 8,267 performance stock units (PSUs) tied to a February 26, 2024 grant and 17,556 PSUs tied to a February 28, 2023 grant, each at an exercise price of $0.0.
The Compensation Committee determined that the performance goals for both PSU grants were achieved. The 2024 grant PSUs are scheduled to vest on February 26, 2027, and the 2023 grant PSUs are scheduled to vest on February 28, 2026, in each case if Guthart remains in continuous service to Intuitive Surgical through those dates.
Intuitive Surgical executive Henry L. Charlton, EVP & Chief Commercial and Marketing, reported the achievement of performance conditions for two performance stock unit (PSU) awards. One award covers 2,861 PSUs granted on February 26, 2024, vesting on February 26, 2027, subject to continued service. The second covers 7,182 PSUs granted on February 28, 2023, vesting on February 28, 2026, also conditioned on ongoing employment.